At Tango, we are committed to patient health, safety and well-being. The patient is part of our process from discovery through to development, and we focus our research and development on areas where we can make a difference in the lives of patients with few or no effective therapeutic options.
We are developing and testing oncology medicines to expand the treatment options for those living with cancer.
STK-11 mutant cancers
Evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of TNG260, with a one cycle single agent run-in phase to evaluate the safety and PK of TNG260, in combination with pembrolizumab, in patients with locally advanced or metastatic solid tumors with an STK11 loss-of-function mutation.
MTAP-deleted cancers
Evaluating safety, pharmacokinetics, pharmacodynamics and efficacy of TNG462 in patients with solid tumors with MTAP deletions.
MTAP-deleted cancers
Evaluating safety, pharmacokinetics, pharmocodynamics, and preliminary clinical activity of TNG908 in patients with MTAP-deleted cancers.
We believe that the best way for patients to access investigational medicines is through a clinical trial. Our clinical trials are listed at ClinicalTrials.gov and include eligibility criteria. If you are interested in learning whether enrollment in a clinical trial is an option for you or someone you know, please consult with the treating physician, who can contact us as needed with questions.
When enrollment in a clinical trial is not an option, and all currently available treatment options have been tried, an investigational medicine may be provided before it is commercially available under programs called Expanded Access or Compassionate Use, which are regulated by the US Food and Drug Administration. Investigational medicines provided by Tango under these circumstances will always be given in accordance with applicable laws and regulations.
The following are some considerations for compassionate use of Tango investigational medicines:
All Compassionate Use requests should come from a treating physician (compassionateuse@tangotx.com) and are evaluated on a case-by-case basis. We answer all such requests as soon as possible (but in any event, within five business days). Physicians who administer Tango investigational medicines through a Compassionate Use program must comply with all applicable laws and regulations and contractual conditions, including those relating to safety reporting.
